Business Context and Reporting Period
Company: Delcath Systems, Inc. (DCTH)
Filing Type: Form 8-K (Current Report)
Date of Report: October 18, 2025
Reporting Period: Preliminary results for the quarter ended September 30, 2025, and full-year 2025 guidance update.
Key Financial Metrics (Q3 2025 Preliminary)
| Metric | Value |
|---|---|
| Total Revenue (CHEMOSAT & HEPZATO KIT) | $20.5 million |
| HEPZATO KIT Revenue | $19.2 million |
| CHEMOSAT Revenue | $1.3 million |
| Gross Margin | 87% (Expected) |
| Net Income | $0.8 million |
| Adjusted EBITDA | $5.3 million |
| Operating Cash Flow | $4.8 million |
| Cash, Cash Equivalents & Short-term Investments | $88.9 million (as of Sept 30, 2025) |
| Debt | $0 |
Material Changes and Clinical Trial Results
The filing highlights significant clinical data from the CHOPIN Trial comparing Delcath's CHEMOSAT Hepatic Delivery System (HDS) with melphalan for percutaneous hepatic perfusion (PHP) alone versus in combination with immune checkpoint inhibitors (ipilimumab and nivolumab) for metastatic uveal melanoma.
- Progression-Free Survival (1-Year): Combination group achieved 54.7% vs. 15.8% for PHP alone (Hazard Ratio 0.34, P<0.001).
- Overall Survival (2-Year): Combination group achieved 49.6% vs. 22.1% for PHP alone (Hazard Ratio 0.39, P=0.006).
- Best Overall Response Rate: Combination group achieved 76.3% vs. 39.5% for PHP alone (P<0.001).
Financially, the company reported a transition to profitability with $0.8 million in net income and positive operating cash flow, driven primarily by HEPZATO KIT sales.
Guidance, Outlook, and Risks
Guidance: The company issued updated full-year 2025 revenue guidance (specific figures not detailed in the text provided, only the announcement of the update).
Risks and Contingencies:
- Preliminary Data: Financial results are unaudited and subject to change upon completion of quarter-end procedures.
- Commercialization: Risks include supply chain management for HEPZATO KIT, FDA inspections of facilities, and implementation of the Risk Evaluation and Mitigation Strategy (REMS).
- Reimbursement: Uncertainty regarding the ability to obtain reimbursement for the HEPZATO KIT.
- Non-GAAP Measures: Adjusted EBITDA is presented as a non-GAAP measure; the company does not provide guidance for net loss or a reconciliation between forecasted Adjusted EBITDA and net loss due to estimation difficulties.
Investor Verification Checklist
- Verify the final audited Q3 2025 financial statements against these preliminary estimates.
- Confirm the specific numerical targets for the updated full-year 2025 revenue guidance in the referenced press release (Exhibit 99.1).
- Monitor regulatory status and FDA inspection outcomes for HEPZATO KIT manufacturing facilities.
- Track reimbursement approvals and commercial uptake rates for the HEPZATO KIT following the CHOPIN trial results.
- Review the reconciliation of Adjusted EBITDA to Net Income in the subsequent 10-Q filing to understand non-GAAP adjustments.